In addition, LINC00617 as a crucial regulator involved in epithelial–mesenchymal transition (EMT) process can positively function on tumor progression and metastasis via activating Sox2 transcription, which makes it possible for LINC00617 severing as a potential therapeutic target in breast cancer [7]. This evidence concerns the gene TUNAR and breast cancer.